Skip to content
Aurobindo Pharma logo

Aurobindo Pharma

AUROPHARMA NSE
₹1,705.00 +10.50 (+0.62%)
P/E
26.60
View as Markdown
MCP
Close 4 Nov 2026 ₹1,705.00 +564.40 +49.5% 1Y
Start ₹1,140.60

Key Fundamentals

MidcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
12.90%
Debt to Equity
0.21
EPS (TTM)
₹64.09
Book Value
₹658.53
Market Cap
—
P/E (TTM)
26.60
P/B
2.59
ROE
10.10%
Dividend Yield
0.24%
EBITDA
₹7,338 Cr
52W High
₹1,740.00
52W Low
₹1,106.00
Day Range
₹1,691.00 – ₹1,724.60
Volume
21,39,005

Peer Comparison

Healthcare › Pharmaceuticals

Aurobindo Pharma peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Aurobindo Pharma (this company)
₹1,705.0026.60₹97,918 Cr2.590.24%10.10%12.90%₹34,935 Cr₹3,711 Cr
Median 8 companies₹1,739.2037.20₹1,25,337 Cr4.570.44%16.25%16.65%₹28,458 Cr₹3,270 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

53 Average

Data confidence 100/100

Category scores

Quality
47
Average
Returns, margins, earnings quality 22% weight
Valuation
78
Strong
Cheap vs sector & own history 24% weight
Growth
21
Poor
Sales & profit trajectory 9% weight
Financial Health
49
Average
Solvency, leverage, coverage 9% weight
Momentum
41
Weak
Trend strength, vol-adjusted 12% weight
Ownership
52
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

4
  • Stock is trading at 2.56 times its book value
  • The company has delivered a poor sales growth of 6.32% over past five years.
  • Company has a low return on equity of 10.8% over last 3 years.
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish4312
OscillatorsBearish432
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
58.39
Neutral
MACD (12,26,9)
3.24
Bullish
SMA (50)
1,667.19
Bullish
SMA (200)
1,464.86
Bullish

As of

Analyst Rating

Based on 26 analysts
BUY62%

16 of 26 analysts rate Buy, 5 Hold, 5 Sell.

As of

BUY
16
62%
HOLD
5
19%
SELL
5
19%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+9.35%
5Y+6.32%
3Y+10.63%
1Y+6.08%
TTM+9.09%

Net profit

Net profit growth by window
10Y+5.64%
5Y−8.07%
3Y+22.02%
1Y+0.55%
TTM+9.47%

Operating cash flow

Operating cash flow growth by window
10Y+14.55%
5Y+10.67%
3Y+32.29%
1Y+40.79%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−2.77 pp
5Y−0.89 pp
3Y+5.50 pp
1Y−0.27 pp
TTM−0.05 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹14,910 Cr
Mar 2018₹16,463 Cr
Mar 2019₹19,564 Cr
Mar 2020₹23,099 Cr
Mar 2021₹24,775 Cr
Mar 2022₹23,455 Cr
Mar 2023₹24,855 Cr
Mar 2024₹29,002 Cr
Mar 2025₹31,724 Cr
Mar 2026₹33,653 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹2,301 Cr
Mar 2018₹2,423 Cr
Mar 2019₹2,364 Cr
Mar 2020₹2,844 Cr
Mar 2021₹5,334 Cr
Mar 2022₹2,647 Cr
Mar 2023₹1,928 Cr
Mar 2024₹3,169 Cr
Mar 2025₹3,484 Cr
Mar 2026₹3,503 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹2,033 Cr −1.2% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 28 Oct 2026
AI opinion · based on fundamentals
Risk medium

Aurobindo Pharma trades at ₹1,644.80 as of 2026-10-28 with a market cap of ₹94,638 Cr and a P/E (TTM) of 25.66x. The stock has delivered a strong 51% return over the past year and sits near its 52-week high of ₹1,740, but carries a modest 10-year compounded profit growth of 6% and a 3-year average ROE of 11%.

Bull Case 7
  • Strong recent stock performance with a 1-year CAGR of 51%, significantly outperforming broader market indices over the same period
  • Low debt-to-equity ratio of 0.21 indicates a conservatively leveraged balance sheet, providing financial flexibility for future investments or acquisitions
  • Compounded profit growth has accelerated to 23% over 3 years, suggesting an improving earnings trajectory compared to the 5-year CAGR of just 1%
  • ROCE of 13.58% reflects reasonable capital efficiency and the ability to generate returns above typical cost-of-capital benchmarks
  • TTM sales growth of 9% and 3-year compounded sales growth of 11% show a revenue pickup relative to the sluggish 5-year CAGR of 6%
  • 10-year compounded sales CAGR of 9% demonstrates a track record of sustained top-line expansion over a long horizon
  • Stock is trading roughly 5.5% below its 52-week high of ₹1,740, indicating the current price level has been validated by recent market participation
Bear Case 8
  • Five-year compounded sales growth of only 6% is weak for a mid-to-large-cap pharma company, raising questions about sustainable top-line momentum
  • Three-year average ROE of approximately 11% and last-year ROE of 10% are below the 10-year average of 14%, indicating declining return efficiency on shareholder equity
  • P/B ratio of 2.50 (reported at 2.56x book value) is elevated for a company generating only 9.25% ROE, implying the market is pricing in significant improvement that may not materialize
  • Potential capitalization of interest costs could be inflating reported profits and understating true operating expenses, warranting scrutiny of accounting quality
  • Dividend yield of just 0.25% offers negligible income return, meaning investors are almost entirely dependent on capital appreciation
  • Five-year compounded profit CAGR of only 1% highlights a prolonged period of earnings stagnation before the recent recovery, questioning the durability of the profit upturn
  • Current ROE of 9.25% is materially below the 10-year average of 14%, suggesting structural margin or capital-allocation headwinds
  • P/E (TTM) of 25.66x on an EPS of ₹64.09 prices the stock at a premium relative to the modest single-digit long-term profit CAGR of 6% over 10 years

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

7h ago

TL;DR: Aurobindo Pharma delivered a strong Q2FY27 with record profit, revenue, and EBITDA, supported by the Lannett acquisition and robust US/Europe markets. No material headwinds emerged this cycle, while corporate restructuring moves (API subsidiary merger, Russia entity transfer) are housekeeping in nature. The margin expansion to 21% and healthy net cash position of $189 million signal solid execution. The trend is improving, and sustaining this momentum will depend on continued integration benefits and pricing stability in key markets.

Positives 2
  • Record Q2 profit up 32.5% Nov 4

    Net profit rose 32.5% YoY to ₹11,238 crore, a record quarter, while revenue grew 23.9% YoY to ₹10,263 crore driven by the Lannett acquisition and strong US/Europe performance.

  • EBITDA margin expands to 21% Nov 4

    EBITDA margin expanded to 21.0% with absolute EBITDA hitting a record ₹2,156 crore. Net cash position stands at $189 million and an interim dividend of ₹7/share was declared.

Neutral 3
  • API subsidiaries merger approved Nov 4

    Board approved merger of wholly owned subsidiaries Auroactive and Apitoria, filed with NCLT Hyderabad, to consolidate API businesses. Apitoria's FY26 turnover of ₹64,431 million far exceeds Auroactive's ₹701 million.

  • Russia stake internal transfer Nov 4

    Approved internal transfer of 100% stake in Auro Pharma LLC to Auropharm Overseas for ~₹29 crore. The Russian subsidiary reported nil turnover across FY24-FY26.

  • Independent Director reappointed Nov 4

    Mangalam Ramasubramanian Kumar reappointed as Independent Director for a second five-year term effective April 1, 2027, subject to shareholder approval.

Quarterly Results

₹ Cr
AUROPHARMA quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
6,851
7,219
7,352
7,580
7,567
7,796
7,979
8,382
7,868
8,286
8,646
8,853
9,150
Expenses
5,702
5,846
5,753
5,920
5,949
6,230
6,401
6,622
6,265
6,608
6,873
7,103
7,271
Operating Profit
1,149
1,373
1,599
1,660
1,618
1,566
1,578
1,760
1,603
1,678
1,773
1,750
1,880
OPM %
17%
19%
22%
22%
21%
20%
20%
21%
20%
20%
21%
20%
21%
Other Income
47
188
163
14
221
136
159
135
107
121
123
117
224
Interest
57
68
76
89
111
113
118
115
98
95
93
98
102
Depreciation
327
418
423
354
404
382
419
444
406
429
465
479
487
PBT
812
1,076
1,262
1,230
1,324
1,207
1,200
1,335
1,207
1,276
1,339
1,291
1,517
Tax %
30%
30%
26%
26%
31%
32%
30%
32%
32%
34%
32%
29%
32%
Net Profit
570
752
940
907
918
817
846
903
824
848
910
921
1,032
EPS (₹)
9.74
12.92
15.98
15.51
15.69
14.07
14.56
15.56
14.2
14.61
15.67
15.86
17.95

Profit & Loss

₹ Cr
AUROPHARMA profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
12,103
13,772
14,910
16,463
19,564
23,099
24,775
23,455
24,855
29,002
31,724
33,653
34,935
Expenses
9,524
10,579
11,469
12,691
15,612
18,249
19,497
19,060
21,148
23,176
25,164
26,783
27,854
Operating Profit
2,579
3,193
3,441
3,772
3,952
4,849
5,278
4,396
3,707
5,826
6,560
6,870
7,081
OPM %
21%
23%
23%
23%
20%
21%
21%
19%
15%
20%
21%
20%
20%
Other Income
81
200
115
105
70
166
3,195
152
291
366
613
404
586
Interest
160
257
67
78
263
305
74
49
140
290
457
384
388
Depreciation
333
392
428
558
668
967
1,055
1,127
1,245
1,522
1,649
1,778
1,859
PBT
2,168
2,744
3,061
3,241
3,091
3,743
7,344
3,373
2,612
4,380
5,066
5,110
5,420
Tax %
28%
26%
25%
25%
24%
24%
27%
22%
26%
28%
31%
31%
—
Net Profit
1,571
2,024
2,301
2,423
2,364
2,844
5,334
2,647
1,928
3,169
3,484
3,503
3,711
EPS (₹)
26.98
34.61
39.29
41.36
40.36
48.56
91.05
45.2
32.9
54.15
60.02
60.34
64.09
Div. Payout %
8%
7%
6%
6%
6%
6%
4%
20%
23%
8%
0%
7%
—

Balance Sheet

₹ Cr
AUROPHARMA balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
29
59
59
59
59
59
59
59
59
59
58
58
Reserves
5,127
7,229
9,313
11,622
13,832
16,766
21,871
24,517
26,781
29,784
32,595
37,833
Borrowings
4,451
5,041
3,364
4,770
6,967
5,826
5,339
2,851
5,286
6,648
8,263
8,073
Other Liabilities
3,303
3,568
3,464
4,492
5,414
6,113
6,147
6,211
7,379
8,227
8,566
12,232
Total Liabilities
12,910
15,896
16,200
20,942
26,271
28,765
33,416
33,638
39,505
44,717
49,482
58,196
Fixed Assets
3,706
4,180
4,834
6,521
8,475
9,396
9,374
10,532
11,024
14,493
14,794
17,407
CWIP
420
848
1,458
1,583
1,668
1,986
3,062
3,747
5,390
3,869
4,900
5,214
Investments
20
123
246
312
360
555
591
997
543
372
252
1,051
Other Assets
8,765
10,745
9,662
12,527
15,768
16,827
20,390
18,362
22,549
25,983
29,536
34,525
Total Assets
12,910
15,896
16,200
20,942
26,271
28,765
33,416
33,638
39,505
44,717
49,482
58,196

Cash Flow

₹ Cr
AUROPHARMA cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1,237
1,420
3,279
1,955
1,651
4,381
3,329
5,016
2,387
2,435
3,925
5,526
Investing
−1,017
−1,446
−1,787
−1,927
−2,904
−1,563
597
−3,211
−3,971
−4,242
−1,866
−2,630
Financing
93
365
−1,915
864
1,919
−1,947
−1,365
−2,969
1,814
800
120
−1,269
Net Cash Flow
313
340
−424
892
666
871
2,561
−1,164
230
−1,007
2,178
1,628
Free Cash Flow
491
−146
1,594
714
114
2,969
1,503
2,693
−323
−1,067
1,408
2,468
CFO/EBITDA
67
67
118
70
61
106
87
143
84
72
86
107

Ratios

AUROPHARMA financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
107
122
68
68
64
68
52
62
66
61
66
77
Inventory Days
239
240
246
317
304
289
333
272
275
284
295
326
Days Payable
136
146
122
128
107
97
103
97
125
129
117
151
Cash Conversion Cycle
210
217
191
257
260
260
282
237
216
216
244
252
Working Capital Days
50
44
51
50
25
35
52
84
55
66
49
44
ROCE %
27%
27%
25%
23%
18%
19%
18%
13%
9%
14%
14%
13%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Aurobindo Pharma insights

70 extracted metrics across FY07–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 51.88%
  • DIIs 24.42%
  • FIIs 17.41%
  • Public 5.02%
  • Others 1.27%

11.99% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Aurobindo Pharma

What does Aurobindo Pharma Ltd do?
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.
Where is Aurobindo Pharma Ltd (AUROPHARMA) listed?
Aurobindo Pharma Ltd trades as AUROPHARMA on the NSE and under code 524804 on the BSE.
Which sector does Aurobindo Pharma Ltd belong to?
Aurobindo Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd trades at a PE ratio of 26.60 as of 4 Nov 2026, on earnings per share of ₹64.09, against a book value of ₹658.53 per share.
What is the 52-week high and low of Aurobindo Pharma Ltd?
Over the last 52 weeks Aurobindo Pharma Ltd has traded between ₹1,106 and ₹1,740 as of 4 Nov 2026.
Does Aurobindo Pharma Ltd pay dividends?
Aurobindo Pharma Ltd has a dividend yield of 0.24%.
What is the Return on Equity (ROE) of Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd reported a return on equity of 10.10%. Its debt-to-equity ratio is 0.21.

Company Information

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Website aurobindo.com
CEO Mr. Kambam Nithyananda Reddy
Employees 27,707
Listed 6 Apr 1995
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AUROPHARMA.md for Aurobindo Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month